Literature DB >> 9151762

Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge.

A C Linthorst1, C Flachskamm, S J Hopkins, M E Hoadley, M S Labeur, F Holsboer, J M Reul.   

Abstract

Corticotropin-releasing hormone (CRH) was infused intracerebroventricularly into rats for 7 d via a miniosmotic pump (1 microg . microl-1 . hr-1). Body temperature and locomotor activity were recorded during the treatment using biotelemetry, whereas hippocampal serotonergic neurotransmission and free corticosterone levels were monitored using in vivo microdialysis on day 7 of CRH treatment. During the microdialysis experiment, behavioral activity was scored by assessing the time during which rats were active (locomotion, grooming, eating, drinking). Continuous intracerebroventricular infusion of CRH produced a transient increase in body temperature and locomotion. Moreover, intracerebroventricularly CRH-treated rats showed elevated free corticosterone levels with no apparent diurnal rhythm. Intraperitoneal administration of bacterial endotoxin -lipopolysaccharide (LPS); 100 microg/kg body weight- on day 7 of CRH/vehicle treatment produced a marked fever response in control animals, which was significantly blunted in intracerebroventricularly CRH-treated rats. Although free corticosterone levels reached similar peak concentrations in both intracerebroventricularly vehicle- and CRH-infused groups after LPS, this response was delayed significantly by approximately 1 hr in the intracerebroventricularly CRH-treated animals. Microdialysis experiments showed no changes in basal extracellular levels of serotonin and 5-hydroxyindoleacetic acid in intracerebroventricularly CRH-infused animals. Injection of LPS in intracerebroventricularly CRH-treated rats produced a blunted 5-HT response and a delayed onset of behavioral inhibition and other signs of sickness behavior. Assessment of the endotoxin-induced cytokine responses showed significantly enhanced plasma interleukin-1 (IL-1) and IL-6 bioactivities in the intracerebroventricularly CRH-infused animals 3 hr after injection of LPS, whereas tumor necrosis factor bioactivity responses were not different. Our data demonstrate that chronically elevated brain CRH levels produce marked changes in basal (largely CRH regulated) physiological and behavioral processes accompanied by aberrant responses to an acute challenge. The present study provides evidence that chronic CRH hypersecretion is an important factor in the etiology of stress-related disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151762      PMCID: PMC6573557     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

Review 1.  Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?

Authors:  A J Dunn; C W Berridge
Journal:  Brain Res Brain Res Rev       Date:  1990 May-Aug

2.  Corticotropin-releasing factor administration elicits a stress-like activation of cerebral catecholaminergic systems.

Authors:  A J Dunn; C W Berridge
Journal:  Pharmacol Biochem Behav       Date:  1987-08       Impact factor: 3.533

3.  Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1.

Authors:  F Berkenbosch; J van Oers; A del Rey; F Tilders; H Besedovsky
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

4.  CRF is involved in the pyrogenic and thermogenic effects of interleukin 1 beta in the rat.

Authors:  N J Rothwell
Journal:  Am J Physiol       Date:  1989-01

5.  Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat.

Authors:  G Luheshi; A J Miller; S Brouwer; M J Dascombe; N J Rothwell; S J Hopkins
Journal:  Am J Physiol       Date:  1996-01

6.  Bioassay of interleukin-1 in serum and plasma following removal of inhibitory activity with polyethylene glycol.

Authors:  S J Hopkins; M Humphreys
Journal:  J Immunol Methods       Date:  1990-10-04       Impact factor: 2.303

7.  Effects of ganglionic blocking agents on behavioral responses to centrally administered CRF.

Authors:  D R Britton; E Indyk
Journal:  Brain Res       Date:  1989-01-30       Impact factor: 3.252

8.  Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients.

Authors:  F C Raadsheer; W J Hoogendijk; F C Stam; F J Tilders; D F Swaab
Journal:  Neuroendocrinology       Date:  1994-10       Impact factor: 4.914

9.  Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis.

Authors:  J Lavicky; A J Dunn
Journal:  J Neurochem       Date:  1993-02       Impact factor: 5.372

10.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

View more
  21 in total

1.  Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor.

Authors:  M L Price; I Lucki
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system.

Authors:  J C Bittencourt; P E Sawchenko
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 3.  The lighter side of BDNF.

Authors:  Emily E Noble; Charles J Billington; Catherine M Kotz; ChuanFeng Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-02-23       Impact factor: 3.619

4.  Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucocorticoid receptor function.

Authors:  I Dijkstra; F J Tilders; G Aguilera; A Kiss; C Rabadan-Diehl; N Barden; S Karanth; F Holsboer; J M Reul
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

5.  Enhanced pelvic responses to stressors in female CRF-overexpressing mice.

Authors:  M Million; L Wang; M P Stenzel-Poore; S C Coste; P Q Yuan; C Lamy; J Rivier; T Buffington; Y Taché
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-12-28       Impact factor: 3.619

6.  Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas.

Authors:  Damián Refojo; Carlos Echenique; Marianne B Müller; Johannes M H M Reul; Jan M Deussing; Wolfgang Wurst; Inge Sillaber; Marcelo Paez-Pereda; Florian Holsboer; Eduardo Arzt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-15       Impact factor: 11.205

7.  Contrasting effects of pretraining, posttraining, and pretesting infusions of corticotropin-releasing factor into the lateral amygdala: attenuation of fear memory formation but facilitation of its expression.

Authors:  Koichi Isogawa; David E A Bush; Joseph E LeDoux
Journal:  Biol Psychiatry       Date:  2012-10-01       Impact factor: 13.382

8.  The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

Authors:  Andrea Peier; Jennifer Kosinski; Kimberly Cox-York; Ying Qian; Kunal Desai; Yue Feng; Prashant Trivedi; Nicholas Hastings; Donald J Marsh
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

9.  Chronic low dose ovine corticotropin releasing factor or urocortin II into the rostral dorsal raphe alters exploratory behavior and serotonergic gene expression in specific subregions of the dorsal raphe.

Authors:  M S Clark; R A McDevitt; B J Hoplight; J F Neumaier
Journal:  Neuroscience       Date:  2007-04-30       Impact factor: 3.590

10.  Lipopolysaccharide-induced hypoactivity and behavioral tolerance development are modulated by the light-dark cycle in male and female rats.

Authors:  Andrew E Franklin; Christopher G Engeland; Martin Kavaliers; Klaus-Peter Ossenkopp
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.